Sugi Predict

Sugi Predict / Compounds / SCHEMBL16027768

SCHEMBL16027768

SCHEMBL16027768

NNC(=O)c1ncc(F)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 3/20 0.59
▸ KDM4E B2RXH2 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ ALPL P05186 3/20 0.38
▸ MPO P05164 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2A6 P11509 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ GAA P10253 3/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ BLM P54132 2/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31589536 0.78 P2RX7 (0.59) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL31538477 0.78 P2RX7 (0.59) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL930305 0.78 P2RX7 (0.59) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL3955429 0.75 P2RX7 (0.55) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL29959449 0.75 ADORA3 (0.37) ALDH1A1SMN1; SMN2KMT2AADORA3AGBL2
SCHEMBL110389 0.75 P2RX7 (1.00) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL31530604 0.74 P2RX7 (0.53) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL108305 0.74 P2RX7 (0.50) P2RX7ALDH1A1SMN1; SMN2GAANPC1
SCHEMBL6221739 0.73 P2RX7 (0.64) P2RX7KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL107626 0.72 BACE1 (0.42) P2RX7KDM4EALDH1A1ALPLGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338243-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-06-24 — — US disclosed
US-20220235062-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-07-28 — — US disclosed
EP-3309161-B1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR JANSSEN PHARMACEUTICA NV (BE) 2019-12-18 — — EP disclosed
EP-3309161-B1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR JANSSEN PHARMACEUTICA NV (BE) 2019-12-18 — — EP disclosed
EP-3191488-B1 P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES JANSSEN PHARMACEUTICA NV (BE) 2019-08-14 — — EP disclosed
US-10053462-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2018-08-21 — — US disclosed
US-10053463-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2018-08-21 — — US disclosed
US-20180118749-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
EP-3309161-A1 P2X7 MODULATORS Janssen Pharmaceutica NV (BE) 2018-04-18 — — EP disclosed
EP-3309161-A1 P2X7 MODULATORS Janssen Pharmaceutica NV (BE) 2018-04-18 — — EP disclosed
US-9102686-B2 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2015-08-11 — — US disclosed
US-9102686-B2 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2015-08-11 — — US disclosed
US-9040534-B2 [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2015-05-26 — — US disclosed
WO-2014152621-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed
WO-2014152537-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed
WO-2014152621-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 — — WO disclosed
US-20140275096-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US disclosed
US-20140275056-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US disclosed
US-20140275056-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US disclosed
US-20140275056-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235062-A1 P2X7 MODULATORS P2RX7, P2RX4, P2RX1 P2RX7 1/4885KDM4E 4071/4885ALDH1A1 1107/4885
US-10053462-B2 P2X7 modulators P2RX1, P2RX5, P2RX7 P2RX7 3/4885KDM4E 2564/4885ALDH1A1 997/4885
US-20140275056-A1 P2X7 MODULATORS P2RX7, P2RX1, P2RX3 P2RX7 1/4885KDM4E 3568/4885ALDH1A1 1353/4885
US-12338243-B2 P2X7 modulators P2RX7, P2RX4, P2RX1 P2RX7 1/4885KDM4E 4071/4885ALDH1A1 1107/4885
US-20140275096-A1 P2X7 MODULATORS P2RX7, P2RX1, P2RX2 P2RX7 1/4885KDM4E 3761/4885ALDH1A1 1441/4885
US-20180118749-A1 P2X7 MODULATORS P2RX7, P2RX3, P2RX1 P2RX7 1/4885KDM4E 4018/4885ALDH1A1 1539/4885
US-10053463-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators HTR5A, P2RX5, P2RX3 P2RX7 4/4885KDM4E 4740/4885ALDH1A1 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.